Protalix BioTherapeutics (PLX) Misses Q4 EPS by 7c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.67 +1.91%
EPS Growth %: -133.3%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -133.3%
Financial Fact:
COST OF REVENUES: -4.25M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q4 EPS of ($0.22), $0.07 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $62.89 million versus the consensus estimate of $6.12 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Geberit AG (GEBN:SW) (GBERY) PT Raised to CHF712 at Jefferies
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
